#Australia #Melbourne #Phase 1 Trial #Malaria Vaccine #Patronus Biotech

Patronus Biotech Receives Ethical Approval for Innovative Malaria Vaccine Trials

GUANGZHOU, China, October 21, 2026 — In a significant advancement in the fight against malaria, Patronus Biotech has officially received ethical approval from Bellberry Limited to initiate Phase 1 clinical trials of three multi-stage malaria vaccines in Australia. This pioneering study represents the company's first foray into human trials, focusing on innovative vaccine candidates designed to combat the complex lifecycle of malaria-causing parasites.

The clinical trial, designated NCT07831226, will investigate three experimental vaccines: LYB014, LYB017, and LYB027. Each vaccine targets crucial stages in the lifecycle of two prevalent malaria parasites: Plasmodium falciparum, which accounts for the majority of severe malaria cases, and Plasmodium vivax, noted for its capacity to remain dormant in the liver. By incorporating viral-like particles (VLP) into their formulation, these vaccines aim for a more extensive immunological response.

A unique aspect of this trial is the adjuvant A02, a novel liposomal adjuvant using entirely synthetic active ingredients. The double-blind, randomized, and dose-escalating study will evaluate the vaccines' safety and immunogenicity in healthy adult volunteers, set to commence recruitment in December 2026 at Nucleus Network Pty Ltd. in Melbourne. Impressive collaboration is underway with Draper Laboratory at Oxford University, leading the immunogenicity analysis.

Despite considerable progress in controlling malaria, it remains one of the world's most pressing public health challenges, resulting in nearly 282 million cases and around 610,000 deaths globally in 2024. The World Health Organization currently endorses RTS,S/AS01 and R21/Matrix-M vaccines, which exclusively target the first stage of P. falciparum’s lifecycle, demonstrating partial efficacy in clinical settings. This limitation is where Patronus Biotech’s trio of vaccines hopes to make a substantial difference.

Each vaccine is meticulously designed to target specific stages of the parasite's lifecycle: LYB014 recognizes critical phases of P. falciparum, LYB017 focuses on P. vivax, while LYB027 approaches both parasites. By addressing remaining phases of the lifecycle that existing vaccines do not, the LYB candidates aspire to build a robust, multi-layered immune defense capable of preventing malaria infection, its associated disease, and further transmission.

Simon Draper, Professor of Vaccinology and Translational Medicine at Oxford's Department of Pediatrics, expressed enthusiastic support for the collaborative venture. He stated, “Malaria remains a significant global health challenge. We must continue exploring new vaccine approaches that can extend protection across various phases of the parasite's lifecycle.”

Dr. Jin, the CEO of Patronus Biotech, expressed confidence in the company’s scientific approach. “Our malaria vaccines and the A02 adjuvant aim not only at infection prevention but also at creating a sustainable, robust defense mechanism to tackle the parasite's complex biology. This could represent a critical step towards malaria elimination.”

With aspirations for a future free from the constraints of malaria, Patronus Biotech is steadfast in its mission. As global healthcare sectors look for more comprehensive solutions to eradicate malaria, the Phase 1 trial signifies a hopeful leap forward in vaccine development.

For further media inquiries, please contact Rebecca Dabbs, Director of Alliances at [email protected].